Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis
Journal of Paediatrics and Child Health · 2026-08 · 62 (8) · 1421-1425
DOI: 10.1111/jpc.70451 ↗At a glance
Journal article in Journal of Paediatrics and Child Health, published online on 2026-06-01. Written by Eliza Szwarcberg and 2 co-authors. Institution: Department of Paediatric Urology, Monash Children's Hospital, Melbourne, Australia. Major MEDLINE topics: Botulinum Toxins, Type A, Nocturnal Enuresis. 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Aim
Monosymptomatic nocturnal enuresis (MNE) significantly impacts many children, with substantial patient groups refractory to conventional first‐line treatments. Intravesical Botox is used for various refractory functional voiding disorders in children, but its efficacy in MNE has not been widely established. This study aimed to determine the efficacy of intravesical Botox in children with refractory monosymptomatic nocturnal enuresis.
Methods
A retrospective analysis was conducted of 22 children with MNE (median age 11 years; 19 males) treated with intravesical Botox injection over a 6 year period. All participants had previously failed desmopressin, and the majority had trialled an enuresis alarm and oxybutynin. Each child received 200iU of Botox injected into the detrusor muscle. Treatment outcomes were classified as complete (100% reduction in wet nights), partial (50%–99% reduction), or no response (0%–49% reduction).
Results
Prior to treatment, median number of wet nights was six per week. Following the final injection, complete response was observed in 8 of 22 (36%) children, partial response in 7 of 22 (32%), and no response in 7 of 22 (32%). Median reduction in wet nights was 2.5 per week. Median duration of response for those experiencing relapse was 11 months. No intra‐operative complications occurred. Post‐operative complications were mild and self‐resolving, limited to transient haematuria/pain and dysuria in isolated cases, with no instances of urinary tract infection or retention.
Conclusions
Intravesical Botox injection is an effective, well‐tolerated treatment option for children with refractory monosymptomatic nocturnal enuresis, demonstrating a sustained response in a significant proportion of patients. This intervention presents a valuable option for treating this multi‐faceted condition.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Paediatric Urology, Monash Children's Hospital, Melbourne, Australia.
- Department of Paediatrics, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
ORCID profiles: Eliza Szwarcberg
Cite
APA
Szwarcberg, E., Kimber, C., & Taghavi, K. (2026). Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis. Journal of Paediatrics and Child Health, 62(8), 1421-1425. https://doi.org/10.1111/jpc.70451
Vancouver
Szwarcberg E, Kimber C, Taghavi K. Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis. Journal of Paediatrics and Child Health. 2026;62(8):1421-1425. doi:10.1111/jpc.70451
BibTeX
@article{Szwarcberg2026,
author = {Szwarcberg, Eliza and Kimber, Chris and Taghavi, Kiarash},
title = {Intravesical Botox: An Effective Therapy for Refractory Monosymptomatic Nocturnal Enuresis},
journal = {Journal of Paediatrics and Child Health},
year = {2026},
volume = {62},
number = {8},
pages = {1421--1425},
doi = {10.1111/jpc.70451}
}
EUVIMED